Showing results (21-30 of 92) with videos related to
Sort By:
Pageof 10
JAMA Neurology|September 4, 2013
Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington diseaseKaren Marder, Yian Gu, Shirley Eberly, et al.Archives of General Psychiatry|February 13, 2003
Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studiesJames Swanson, Suneel Gupta, Andrew Lam, et al.Clinical Genetics|May 17, 2019
The choice not to undergo genetic testing for Huntington disease: Results from the PHAROS studyKaren E Anderson, Shirley Eberly, Karen S Marder, et al.Journal of Huntington'S Disease|December 17, 2016
Risk Factors for Suicidal Ideation in People at Risk for Huntington's DiseaseKaren E Anderson, Shirley Eberly, Mark Groves, et al.Movement Disorders : Official Journal of the Movement Disorder Society|June 3, 2008
The relationship between CAG repeat length and clinical progression in Huntington's diseaseBernard Ravina, Megan Romer, Radu Constantinescu, et al.Neurology|April 25, 2014
Longitudinal follow-up of SWEDD subjects in the PRECEPT StudyKenneth Marek, John Seibyl, Shirley Eberly, et al.American Journal of Medical Genetics. Part A|July 16, 2008
Fear of health insurance loss among individuals at risk for Huntington diseaseEmily Oster, E Ray Dorsey, Jan Bausch, et al.Movement Disorders : Official Journal of the Movement Disorder Society|May 4, 2011
Serum urate and probability of dopaminergic deficit in early "Parkinson's disease"Michael A Schwarzschild, Kenneth Marek, Shirley Eberly, et al.Movement Disorders : Official Journal of the Movement Disorder Society|July 30, 2010
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's diseaseSteven R Schwid, Janice Bausch, David Oakes, et al.Neurology|April 30, 2013
Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROSAnnie Killoran, Kevin M Biglan, Joseph Jankovic, et al.Pageof 10